Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
OmniAb, Inc. (OABI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.83-6.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for OABI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash and equivalents at least $33 million by end 2026 | Cash targets also improved to $33-38 million by year-end 2026. | Intact | Cash falls below $33 million at end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “As of September 30, 2026, OmniAb had cash, cash equivalents and short-term investments of $64.2 million.” “The Company now expects to end the year with cash and cash equivalents in the range of $53 million to $57 million, versus $49 million to $53 million previously.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
OABI is an early-stage, loss-making growth business, with a thesis built around licensing, partnerships, and new products rather than steady current earnings. The long-term thesis is intact, though recent momentum weakened after the latest results and overall risk is elevated.
Valuation is stretched, at a reported 1.75 times the peer comparison, and expectations appear to include some re-rating, or a change in how the market values the business. The expectations gap is 0.19, but the snapshot does not explain its scale; the evidence therefore gives only a limited view of what the market already assumes.
For the near term, management has raised 2026 revenue guidance, and the new Lilly collaboration supports the licensing and partnership strategy. However, quarterly revenue has varied, year-to-date growth was mainly milestone revenue, and the company remains loss-making. xPloration revenue is still limited, while cost progress is mixed; recent momentum also softened after earnings.
The multi-year case depends on higher guidance translating into durable revenue, and on xPloration and OmniTides gaining commercial traction. A guidance reversal would damage credibility, while weaker employment data could weigh on cyclical businesses; continued strength among large Healthcare companies could support the sector backdrop.
Over the next 1 to 3 years, OABI’s thesis rests on converting partnerships and product launches into repeatable revenue while controlling costs. The opportunity is paired with elevated risk and stretched valuation, and execution remains the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrows toward -$0.32 or better by 2027 | A supporting condition in OmniAb, Inc.'s published investment case. The stated target is <= -0.32 USD_PER_SHARE. | Improving | EPS loss worsens beyond -$0.32 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $28 million in 2026 | A primary condition in OmniAb, Inc.'s published investment case. The stated target is >=28 USD_MILLIONS. | Intact | Revenue falls below $28 million in FY26 | Revenue: $3.993M FY2026-Q3; GAAP. Published target: >=28 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Oct 30, 20263,993,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.32 → $-0.26 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-25 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-26 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-27 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-28 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-07-29 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-30 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-07-31 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-01 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-02 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-08-03 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-04 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-08-05 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-06 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-07 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-08 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-08-09 | $-0.32 | $46,106,500 | 4 / 6 |
| 2026-08-10 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-12 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-13 | $-0.30 | $43,295,500 | 4 / 6 |
| 2026-08-14 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-15 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-16 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-17 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-18 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-19 | $-0.27 | $46,106,500 | 4 / 5 |
| 2026-08-20 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-21 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-22 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-23 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-24 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-25 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-26 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-27 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-28 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-29 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-30 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-08-31 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-01 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-02 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-03 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-04 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-05 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-06 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-07 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-08 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-09 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-10 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-11 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-12 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-13 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-14 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-15 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-16 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-17 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-18 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-19 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-20 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-21 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-22 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-23 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-24 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-25 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-26 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-27 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-28 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-29 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-09-30 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-01 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-02 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-03 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-04 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-05 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-06 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-07 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-08 | $-0.28 | $43,491,500 | 3 / 5 |
| 2026-10-09 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-10 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-11 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-12 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-13 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-14 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-15 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-16 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-17 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-18 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-19 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-20 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-21 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-22 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-23 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-24 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-25 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-26 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-27 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-28 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-29 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-30 | $-0.27 | $43,912,333 | 3 / 5 |
| 2026-10-31 | $-0.27 | $46,296,500 | 3 / 5 |
| 2026-11-01 | $-0.27 | $46,296,500 | 3 / 4 |
| 2026-11-02 | $-0.26 | $46,993,167 | 4 / 4 |
| 2026-11-03 | $-0.26 | $46,993,167 | 4 / 5 |
| 2026-11-04 | $-0.26 | $46,993,167 | 4 / 5 |
| 2026-11-05 | $-0.26 | $46,993,167 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.